T cell-mediated lung ischemia-reperfusion injury
T细胞介导的肺缺血再灌注损伤
基本信息
- 批准号:8267659
- 负责人:
- 金额:$ 38.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-01 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcuteAddressAdoptive TransferAlveolarAlveolar MacrophagesAntibodiesAntigensBlocking AntibodiesBone MarrowBone Marrow TransplantationCD4 Positive T LymphocytesCellsChronicClinical ResearchCoculture TechniquesComplicationDataDendritic CellsDevelopmentDiphtheria ToxinFutureImmuneIn VitroInfiltrationInflammationInflammatoryInflammatory ResponseInjuryInterferonsInterleukin-17Interleukin-6IschemiaKnock-outKnockout MiceKnowledgeLaboratoriesLeukocytesLungLung InflammationLung TransplantationMacrophage ActivationMeasuresMediatingMediator of activation proteinMusNADPH OxidaseNeutrophil InfiltrationOutcomeOxidative StressPathway interactionsPhagocytesPostoperative PeriodProcessProductionReactive Oxygen SpeciesReperfusion InjuryReperfusion TherapyRespiratory physiologyRoleSourceT-Cell ActivationT-LymphocyteTNF geneTestingTransgenic MiceTransplant RecipientsTransplantationTumor Necrosis Factor-alphaWild Type Mousecytokinedesignhuman TNF proteinimprovedin vivoin vivo Modelinterleukin-23lung injurylung ischemiamacrophagemortalityneutrophilpublic health relevancesmall molecule
项目摘要
DESCRIPTION (provided by applicant): Ischemia-reperfusion (IR) injury remains a major source of early mortality after lung transplantation. The objective of this proposal is to better understand the cellular mechanisms that initiate and mediate this inflammatory process. Our laboratory has established that lung IR injury is dependent on alveolar macrophage activation, CD4+ T cell infiltration, and TNF-alpha induction. Recent data also supports an important role for IL-17 and IL-17-producing CD4+ T cells, such as iNKT, in mediating lung inflammation after IR. Thus Aim 1 will determine if iNKT cells initiate lung IR injury and neutrophil infiltration via IL-17 production. Oxidative stress and the release of reactive oxygen species via NADPH oxidase is also a component of IR injury as well as phagocytic cell activation. Thus Aim 2 will determine if NADPH oxidase-generated ROS is a key mechanism for the activation of iNKT cells after IR. Our overall hypothesis is that lung IR injury is initiated through CD4+ iNKT cell activation via production of IL-17 and NADPH oxidase-dependent ROS. Results from this proposal will help design successful strategies to improve outcomes in lung transplant recipients.
PUBLIC HEALTH RELEVANCE: Project Narrative: Lung reperfusion injury is a major complication after transplantation resulting in dangerous inflammation, higher post-operative mortality, and late complications including chronic rejection. The objective of this proposal is to better understand the cellular mechanisms that initiate and mediate lung reperfusion injury. Results from this proposal will help design successful strategies to improve outcomes in lung transplantations.
描述(由申请人提供):肺移植后早期死亡的一个主要来源是缺血再灌注损伤。这项建议的目的是更好地了解启动和调节这一炎症过程的细胞机制。我们的实验室已经证实,肺IR损伤依赖于肺泡巨噬细胞的激活、CD4+T细胞的浸润和肿瘤坏死因子-α的诱导。最近的数据也支持产生IL-17和IL-17的CD4+T细胞,如iNKT,在IR后的肺部炎症中起重要作用。因此,目标1将确定iNKT细胞是否通过产生IL-17启动肺IR损伤和中性粒细胞浸润。氧化应激和通过NADPH氧化酶释放的活性氧物种也是IR损伤和吞噬细胞激活的一个组成部分。因此,目标2将确定NADPH氧化酶产生的ROS是否是IR后iNKT细胞激活的关键机制。我们的总体假设是肺IR损伤是通过产生IL-17和NADPH氧化酶依赖的ROS来激活CD4+iNKT细胞而开始的。这项建议的结果将有助于设计成功的策略,以改善肺移植接受者的结果。
公共卫生相关性:项目描述:肺再灌注损伤是移植后的一个主要并发症,导致危险的炎症、较高的手术后死亡率和包括慢性排斥反应在内的晚期并发症。这项建议的目的是为了更好地了解启动和介导肺再灌注损伤的细胞机制。这项建议的结果将有助于设计成功的策略,以改善肺移植的结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Victor E Laubach其他文献
Victor E Laubach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Victor E Laubach', 18)}}的其他基金
Role of TRPV4 channel signaling in lung ischemia-reperfusion injury
TRPV4通道信号在肺缺血再灌注损伤中的作用
- 批准号:
10181419 - 财政年份:2021
- 资助金额:
$ 38.12万 - 项目类别:
Role of TRPV4 channel signaling in lung ischemia-reperfusion injury
TRPV4通道信号在肺缺血再灌注损伤中的作用
- 批准号:
10586084 - 财政年份:2021
- 资助金额:
$ 38.12万 - 项目类别:
Role of TRPV4 channel signaling in lung ischemia-reperfusion injury
TRPV4通道信号在肺缺血再灌注损伤中的作用
- 批准号:
10391559 - 财政年份:2021
- 资助金额:
$ 38.12万 - 项目类别:
Pannexin-1 Signaling in Lung Ischemia-Reperfusion Injury
肺缺血再灌注损伤中的 Pannexin-1 信号转导
- 批准号:
9898429 - 财政年份:2017
- 资助金额:
$ 38.12万 - 项目类别:
Resident Leukocytes in Lung Ischemia-Reperfusion Injury
肺缺血再灌注损伤中的驻留白细胞
- 批准号:
7057840 - 财政年份:2005
- 资助金额:
$ 38.12万 - 项目类别:
Resident Leukocytes in Lung Ischemia-Reperfusion Injury
肺缺血再灌注损伤中的驻留白细胞
- 批准号:
6919071 - 财政年份:2005
- 资助金额:
$ 38.12万 - 项目类别:
T cell-mediated lung ischemia-reperfusion injury
T细胞介导的肺缺血再灌注损伤
- 批准号:
8490408 - 财政年份:2005
- 资助金额:
$ 38.12万 - 项目类别:
T cell-mediated lung ischemia-reperfusion injury
T细胞介导的肺缺血再灌注损伤
- 批准号:
7985780 - 财政年份:2005
- 资助金额:
$ 38.12万 - 项目类别:
Resident Leukocytes in Lung Ischemia-Reperfusion Injury
肺缺血再灌注损伤中的驻留白细胞
- 批准号:
7409219 - 财政年份:2005
- 资助金额:
$ 38.12万 - 项目类别:
Resident Leukocytes in Lung Ischemia-Reperfusion Injury
肺缺血再灌注损伤中的驻留白细胞
- 批准号:
7227088 - 财政年份:2005
- 资助金额:
$ 38.12万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 38.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 38.12万 - 项目类别:
Operating Grants